Director appointment

RNS Number : 8673N
Tavistock Investments PLC
26 January 2023
 

Tavistock Investments Plc

("Tavistock" or the "Company")

 

Director appointment

 

26 January 2023

 

Tavistock is pleased to announce the appointment of Johanna Rager as a director of the Company with immediate effect. Johanna joined Tavistock in 2019 and is the Group's Finance and Operations Director.


Prior to joining Tavistock, Johanna held senior management positions at Thermo Fisher Scientific Inc. and Parexel International Ltd for over 20 years.

The following disclosures are made in accordance with the AIM Rules for Companies:

Johanna Martina Gabriela Rager-Badesha (formerly Johanna Martina Gabriela Rager), aged 53, is or has been a director or partner of the following companies and partnerships in the past five years:

Current directorships/partnerships: 

 

Directorships and partnerships held within the last five years:

Tavistock Chater Allan LLP


Cornerstone Asset Holdings Limited


Duchy Independent Financial Advisers Limited


Tavistock Asset Management Limited


Tavistock Estate Planning Services Limited


Tavistock Group Holdings Limited


Tavistock Partners (UK) Limited


Tavistock Partners Limited


Tavistock Services Limited


The Tavistock Partnership Limited


Tavistock Select LLP


Johanna Martina Gabriela Rager-Badesha beneficially holds 2,276,000 ordinary shares in the Company.

Save for the information set out above, there are no further disclosures to be made in accordance with Rule 17, Schedule 2(g) of the AIM Rules for Companies in respect of the appointment of Johanna.

For further information:

 

Tavistock Investments Plc

Oliver Cooke

Brian Raven

 

Tel: 01753 867000

Allenby Capital Limited

(Nominated adviser and broker)

Corporate Finance: Nick Naylor, Nick Athanas, Dan Dearden-Williams

Sales and Corporate Broking: Tony Quirke

 

Tel: 020 3328 5656

Powerscourt

Gilly Lock

Roxane Girard  

Tel: 07711 380 007

  020 7250 1446

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOABAMJTMTATBPJ
UK 100